Abstract
Demonstrating the relationship between Australia antigen and hepatitis B virus in the late 1960’s created a serologic means for detecting hepatitis B infection, disease, carriers, and recovery (1,2). This information provided an impetus for vaccine development even in the absence of a means to propagate the virus in the laboratory. Individuals chronically infected with hepatitis B could be identified and their infected plasma containing infectious hepatitis B virus (HBV) or Dane particles and excess hepatitis B surface antigen (HBsAg) obtained by plasmaphoresis (3). Additional markers (shown in Figure 1) of human hepatitis B infection and recovery were further identified as important serologic markers. These include hepatitis B surface antigen (HBsAg) and its antibody (anti-HBs), hepatitis B core antigen and its antibody (anti-HBc), and the hepatitis Beantigen and its antibody (anti-HBe). By use of these and other tests, it is possible to identify susceptibles from immunes and the probable state of infection of the carriers. Persons who have never had hepatitis B are free of all markers.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Prince, A. M. (1968). An antigen detected in the blood during the incubation period of serum hepatitis, Proc. Natl. Acad. Sci. 60:814–821.
Krugman, S., et al. (1971). Viral hepatitis, type B (MS-2 strain). Studies on active immunization. J. Am. Med. Assoc. 217:41–45.
Vyas, G. N., Cohen, S. N., and Schmid, R. (1978). Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention, Franklin Institute Press, Philadelphia.
McAuliffe, V. J., et al. (1980). Type B hepatitis: A review of current prospects for a safe and effective vaccine. Rev. Infect. Dis. 2:470–492.
Hilleman, M. R., McAlleer, W. J., and McLean, A. A. (1981). Human Hepatitis B Vaccine, Proc. Europ. Symp. on Hepatitis B, KPR Inform/Media, New York, pp. 120–139.
Szmuness, W., et al. (1978). Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N. Engl. J. Med. 303:833–841.
Francis, D. P., et al. (1982). The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann. Intern. Med. 97:362–366.
Szmuness, W., Alter, J. H., and Maynard, J. E. (1981). Viral Hepatitis, 1981 International Symposium, Franklin Institute Press, Philadelphia.
Morbidity and Mortality Weekly Report 31:317–322; 327–328, 1982.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer Science+Business Media New York
About this chapter
Cite this chapter
Weibel, R.E. (1984). Hepatitis B Vaccine Trials, Experience and Review. In: Millman, I., Eisenstein, T.K., Blumberg, B.S. (eds) Hepatitis B. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0369-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0369-3_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0371-6
Online ISBN: 978-1-4899-0369-3
eBook Packages: Springer Book Archive